You are here

  • Home
  • Archive
  • Volume 66, Issue 3
  • Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

Article Text

Article menu

This article has Replies. Please see:

Download PDFPDF

PostScript
Letter
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis
Free
  1. Federico Alghisi1,
  2. Paolo Palma2,
  3. Enza Montemitro1,
  4. Stefania Bernardi2,
  5. Giuseppe Pontrelli2,
  6. Paolo Rossi2,
  7. Vincenzina Lucidi1
  1. 1Department of Pediatric Medicine, Unit of Cystic Fibrosis, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
  2. 2University Department of Pediatrics, DPUO, Clinical Trial Center, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
  1. Correspondence to Vincenzina Lucidi, Department of Pediatric Medicine, Unit of Cystic Fibrosis, Bambino Gesù Children's Hospital, P.zza S. Onofrio n. 4, 00165 Rome, Italy; vincenzina.lucidi{at}opbg.net

http://dx.doi.org/10.1136/thx.2010.156018

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Viral respiratory tract infections may determine lung function deterioration in patients affected by cystic fibrosis (CF). Viruses may have a synergistic action with bacteria to damage the respiratory tract; they may also promote airway bacterial colonisation.1 Influenza virus infection has been described to increase the number of CF pulmonary exacerbations and the incidence of hospitalisation.2 For this reason, vaccination is strongly recommended annually. The immunogenic effect and safety of influenza vaccines in CF children are comparable with that of healthy individuals.3 The reported adverse events after vaccination are mild and not persisting. In 2009, a novel swine pandemic influenza A virus (A/H1N1) was identified. To date, the …

    View Full Text

    Linked Articles